Ligand Pharmaceuticals (LGND) Convertible Debt (2014 - 2022)
Ligand Pharmaceuticals (LGND) posted Convertible Debt of $176.5 million for Q1 2022, down 44.95% sequentially from $320.7 million in Q4 2021, and down 49.89% YoY from $352.3 million in Q1 2021.
Ligand Pharmaceuticals (LGND) Convertible Debt (2014 - 2022) Analysis & Trends
Ligand Pharmaceuticals has reported Convertible Debt for 9 years, with the latest figure at $176.5 million in Q1 2022.
- Quarterly Convertible Debt fell 49.89% year-over-year to $176.5 million in Q1 2022, while the trailing twelve-month figure through Mar 2022 was $176.5 million (down 49.89% YoY) and the FY2021 annual result came in at $320.7 million, down 27.49% from the prior year.
- Convertible Debt eased to $176.5 million in Q1 2022 per LGND's latest filing, from $320.7 million in the prior quarter.
- Over five years, Convertible Debt peaked at $639.0 million in Q4 2019 and troughed at $16.1 million in Q1 2018.
- A 5-year average of $447.6 million and a median of $449.7 million in 2020 frame the typical range for Convertible Debt.
- The sharpest annual moves came in 2019 and 2022: Convertible Debt soared 3737.46% in 2019, then sank 49.89% in 2022.
- Over 5 years, Convertible Debt stood at $609.9 million in 2018, then rose by 4.77% to $639.0 million in 2019, then tumbled by 30.78% to $442.3 million in 2020, then retreated by 27.49% to $320.7 million in 2021, then sank by 44.95% to $176.5 million in 2022.
- According to Business Quant data, Convertible Debt over the past three periods registered $176.5 million, $320.7 million, and $316.9 million for Q1 2022, Q4 2021, and Q3 2021 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Ligand Pharmaceuticals | 5.87 Bn | 4.51 Bn | 60.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2022 | 176.54 Mn |
| Dec 31, 2021 | 320.72 Mn |
| Sep 30, 2021 | 316.89 Mn |
| Jun 30, 2021 | 315.32 Mn |
| Mar 31, 2021 | 352.31 Mn |
| Dec 31, 2020 | 442.29 Mn |
| Sep 30, 2020 | 454.97 Mn |
| Jun 30, 2020 | 449.67 Mn |
| Mar 31, 2020 | 444.43 Mn |
| Dec 31, 2019 | 638.96 Mn |
| Sep 30, 2019 | 631.53 Mn |
| Jun 30, 2019 | 624.21 Mn |
| Mar 31, 2019 | 616.99 Mn |
| Dec 31, 2018 | 609.86 Mn |
| Sep 30, 2018 | 602.84 Mn |
| Jun 30, 2018 | 595.91 Mn |
| Mar 31, 2018 | 16.08 Mn |
| Dec 31, 2017 | 18.90 Mn |
| Sep 30, 2017 | 21.60 Mn |
| Jun 30, 2017 | 24.29 Mn |